Efficacy and safety of continuing vs. withdrawing adalimumab therapy in maintaining remission of non-radiographic axial spondyloarthritis

The multinational ABILITY-3 trial tracked the incidence of flare in patients who achieved remission of non-radiographic axial spondyloarthritis with adalimumab, stratified according to whether they continued to take the drug afterwards or ended its use. The researchers recruited 673 adults, 45% of whom went into sustained remission.

The multinational ABILITY-3 trial tracked the incidence of flare in patients who achieved remission of non-radiographic axial spondyloarthritis with adalimumab, stratified according to whether they continued to take the drug afterwards or ended its use. The researchers recruited 673 adults, 45% of whom went into sustained remission. Of those 305 participants, one-half were blindly randomized to keep taking adalimumab while the others were randomized to discontinue the therapy and take a placebo instead. Up to and including week 68, 70% of the adalimumab continuation patients were flare-free, which was significantly greater than the 47% of withdrawal patients who did not experience a flare.